ストックスクリーナーアプリを入手
17.95
4.88%
-0.92
アフターアワーズ：
18.26
0.31
+1.73%
前日終値:
$18.87
開ける：
$18.89
24時間の取引高:
1.11M
Relative Volume:
0.81
時価総額：
$830.44M
収益：
$82.71M
当期純損益:
$-102.24M
株価収益率:
-4.891
EPS:
-3.67
ネットキャッシュフロー:
$-76.57M
1週間 パフォーマンス:
-4.47%
1か月 パフォーマンス:
-5.13%
6か月 パフォーマンス:
+53.95%
1年 パフォーマンス:
+29.60%
1日の値動き範囲:
$17.89
$18.89
1週間の範囲:
$17.89
$18.93
52週間の値動き範囲:
$3.42
$21.71
Urogen Pharma Ltd Stock (URGN) Company Profile
URGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
17.95 | 873.00M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-06-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-19 | 再開されました | Ladenburg Thalmann | Buy |
| 2024-08-22 | 開始されました | Guggenheim | Buy |
| 2023-02-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-04-27 | 開始されました | Berenberg | Buy |
| 2020-04-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-09 | 開始されました | National Securities | Neutral |
| 2019-05-30 | 開始されました | JP Morgan | Neutral |
| 2019-05-29 | 開始されました | Goldman | Neutral |
| 2019-01-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-04-04 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-11-15 | 繰り返されました | Oppenheimer | Outperform |
| 2017-11-15 | ダウングレード | Raymond James | Outperform → Mkt Perform |
すべてを表示
Urogen Pharma Ltd (URGN) 最新ニュース
Goldman Sachs Group Inc. Sells 33,188 Shares of Urogen Pharma $URGN - MarketBeat
IPO Launch: What is UroGen Pharma Ltds 5 year growth outlook2025 Analyst Calls & Risk Managed Investment Entry Signals - khodrobank.com
Urogen Pharma (NASDAQ:URGN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Aug Sectors: How cyclical is UroGen Pharma Ltd.’s revenue stream2025 Historical Comparison & High Return Stock Watch Alerts - khodrobank.com
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Position in Urogen Pharma $URGN - MarketBeat
Is it too late to sell UroGen Pharma Ltd.Market Performance Report & Free Fast Entry Momentum Trade Alerts - newser.com
Aug Breakouts: What is Piedmont Office Realty Trust Inc. s revenue forecastMarket Activity Report & Capital Protection Trade Alerts - khodrobank.com
Buybacks Report: Will UroGen Pharma Ltd benefit from rate cutsGold Moves & Daily Volume Surge Trade Alerts - خودرو بانک
Surprises Report: Is UroGen Pharma Ltd. benefiting from innovation trendsQuarterly Growth Report & Expert-Curated Trade Recommendations - khodrobank.com
Urogen Pharma $URGN Shares Sold by Trexquant Investment LP - MarketBeat
Investment Recap: Will UroGen Pharma Ltd. benefit from rising consumer demand2025 Geopolitical Influence & Fast Momentum Entry Tips - khodrobank.com
Smart Money: Can UroGen Pharma Ltd ride the EV wave2025 Analyst Calls & Verified Trade Idea Suggestions - khodrobank.com
Urogen Pharma (NASDAQ:URGN) Shares Down 8% Following Insider Selling - MarketBeat
Big Money Moves: Will UroGen Pharma Ltd benefit from rate cutsJuly 2025 Chart Watch & Reliable Breakout Forecasts - khodrobank.com
Volume Summary: What analysts say about UroGen Pharma Ltd stock2025 Geopolitical Influence & AI Powered Trade Plan Recommendations - khodrobank.com
Earnings Miss: What analysts say about UroGen Pharma Ltd stock2025 Sector Review & Fast Moving Trade Plans - خودرو بانک
Treasury Yields: Is UroGen Pharma Ltd a cyclical or defensive stock2025 Bull vs Bear & Low Risk High Reward Trade Ideas - khodrobank.com
Aug Shorts: Will UroGen Pharma Ltd face regulatory challenges2025 Winners & Losers & Safe Entry Zone Tips - khodrobank.com
Aug Action: How cyclical is UroGen Pharma Ltd.’s revenue stream2025 Technical Patterns & Expert Verified Movement Alerts - khodrobank.com
What machine learning models say about UroGen Pharma Ltd.2025 Price Momentum & Verified Swing Trading Watchlists - newser.com
Stop Loss: What are the risks of holding UroGen Pharma LtdWeekly Gains Report & Weekly Watchlist of Top Performers - خودرو بانک
Breakout Watch: Can UroGen Pharma Ltd. stock outperform in a bear marketEarnings Performance Report & Technical Pattern Based Signals - خودرو بانک
US Market Wrap: Can UroGen Pharma Ltd. disrupt its industryStock Surge & Stepwise Entry/Exit Trade Alerts - khodrobank.com
Trend analysis for UroGen Pharma Ltd. this weekWeekly Trend Recap & Technical Pattern Based Signals - newser.com
Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares - MarketBeat
Urogen Pharma (NASDAQ:URGN) Shares Up 10.6%Time to Buy? - MarketBeat
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year HighHere's Why - MarketBeat
Urogen Pharma (NASDAQ:URGN) Raised to Hold at Wall Street Zen - Defense World
Parkman Healthcare Partners LLC Has $4.35 Million Holdings in Urogen Pharma $URGN - MarketBeat
Adage Capital Partners GP L.L.C. Sells 1,651,086 Shares of Urogen Pharma $URGN - MarketBeat
Brokerages Set Urogen Pharma (NASDAQ:URGN) PT at $32.00 - MarketBeat
Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 Shares - MarketBeat
UroGen Pharma’s chief medical officer Schoenberg sells $16k in shares - Investing.com India
Urogen Pharma (URGN) general counsel sells $29k in shares - Investing.com India
Urogen Pharma (URGN) general counsel sells $29k in shares By Investing.com - Investing.com Nigeria
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st
UroGen Pharma at H.C. Wainwright Conference: Zosduri’s Market Impact By Investing.com - Investing.com Australia
UroGen Pharma at H.C. Wainwright Conference: Zosduri’s Market Impact - Investing.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
UroGen Pharma (URGN) Awards Restricted Stock Units to New Employ - GuruFocus
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing R - GuruFocus
Urogen Pharma announces inducement grants under Nasdaq Listing Rule - MarketScreener
67,700 Shares: UroGen Pharma Expands Team with 40 New Hires to Drive Cancer Treatment Portfolio Growth - Stock Titan
Urogen Pharma Ltd (URGN) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
0.09%
大文字化:
|
ボリューム (24 時間):